Drugs / Pegylated Lipoxomal Doxorubicin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01379989 | Jun 2011 → Dec 2020 | ovarian cancer | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Lipoxomal Doxorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01379989 ↗ |
| Route | Intravenous | “PLD 30 mg/m² i.v.” NCT01379989 ↗ |